Skip to content

Author

Douglas S. Hawkins

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N)

Abstract Background This is a phase II subprotocol of the National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial evaluating selpercatinib, a RET inhibitor, in children and young adults aged 1-21 years with relapsed or refractory soli...

Andrea T. Franson, Samara L. Potter, P. Williams et al. · 0 citations
Open access Sep 2026

Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study.

PURPOSE Identification of discrete risk groups remains a high priority for patients with Ewing sarcoma (EWS). We sought to prospectively validate circulating tumor DNA (ctDNA) as a prognostic factor and develop clinical-molecular risk groups. METHODS We conducted a prospective investigator-initiated biology study for...

D. Shulman, Kelly S. Klega, Nan Chen et al. · 0 citations
Open access Sep 2026

The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology

Quantitative co-clinical imaging provides a powerful framework to link genotype with function by confirming drug delivery, target engagement, pharmacodynamic effects, tumor function and heterogeneity across animal models and patients to advance functional precision medicine (FPM).

K. Shoghi, C. Badea, Donna M. Peehl et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.